US6774227B1ExpiredUtility

Therapeutic uses of factors which inhibit or neutralize MIF activity

Assignee: CYTOKINE PHARMASCIENCES INCPriority: May 17, 1993Filed: Oct 24, 1996Granted: Aug 10, 2004

Est. expiryMay 17, 2013(expired)· nominal 20-yr term from priority

Inventors:Richard J. Bucala Jason Chesney

C07K 16/24A01K 2227/105A61K 48/00C12N 2310/315C07K 2317/73A01K 2217/05A61P 43/00A61P 35/00C12N 15/8509A61K 38/00C12N 15/1138C12N 15/113A61K 2039/505C07K 16/26C07K 14/575A01K 2267/0337A01K 2267/03A01K 2217/075C07K 14/52A01K 2267/0331A01K 67/0271C07K 14/72C12N 15/1136

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to methods of treating disorders related to cellular overproliferation comprising neutralizing the production or activity of macrophage migration inhibitory factor (MIF). The invention also relates to therapeutic compositions comprising factors which inhibit or neutralize MIF activity, such as, MIF antisense RNA molecules and MIF monoclonal antibodies and derivatives or analogs thereof. The invention further relates to the uses of such compositions and methods for the treatment of malignancies, including, but not limited to, B and T cell lymphomas.

Claims

exact text as granted — not AI-modified

What is claimed is:  
     
       1. An antisense molecule that is complementary to MIF mRNA and consists of the following nucleotide sequence: 
       5′ ATG AAC ATC GGC ATG ATG GC 3′ [SEQ ID NO: 2].

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.